130 related articles for article (PubMed ID: 24217238)
1. Long-term outcomes following alemtuzumab induction in lung transplantation.
Wehman B; Griffith BP; Balwan A; Kon ZN; Suffredini DA; Evans C; Garcia JP; Iacono A
Heart Surg Forum; 2013 Oct; 16(5):E252-6. PubMed ID: 24217238
[TBL] [Abstract][Full Text] [Related]
2. Early outcomes using alemtuzumab induction in lung transplantation.
van Loenhout KC; Groves SC; Galazka M; Sherman B; Britt E; Garcia J; Griffith B; Iacono A
Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):190-4. PubMed ID: 19939852
[TBL] [Abstract][Full Text] [Related]
3. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.
Jaksch P; Ankersmit J; Scheed A; Kocher A; Muraközy G; Klepetko W; Lang G
Am J Transplant; 2014 Aug; 14(8):1839-45. PubMed ID: 25039364
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
13. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation.
Treede H; Glanville AR; Klepetko W; Aboyoun C; Vettorazzi E; Lama R; Bravo C; Knoop C; Aubert JD; Reichenspurner H;
J Heart Lung Transplant; 2012 Aug; 31(8):797-804. PubMed ID: 22554673
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
19. Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.
Li KHC; Ho JCS; Recaldin B; Gong M; Ho J; Li G; Liu T; Wu WKK; Wong MCS; Xia Y; Dong M; Tse G;
Transplant Proc; 2018 Dec; 50(10):3723-3731. PubMed ID: 30577263
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
